Why did Chemours' stock rise 5.4% even though three Wall Street firms cut their price targets?

Chemours' stock rose 5.4% despite downward price target revisions from JP Morgan, BMO Capital, and UBS because the market reaction suggests investors may have already priced in those cuts or perceive potential upside from the newly revised targets.

What specific action did JP Morgan take regarding Chemours, and how does it differ from the other two firms mentioned?

JP Morgan maintained its Neutral rating on Chemours while lowering its price target to $15; this contrasts with the other two firms—BMO Capital and UBS—whose specific rating actions are not disclosed in the text, only that they also cut their price targets.

Chemours Jumps 5.4% After JP Morgan Maintains Neutral

Aug 14, 2026

Chemours shares rose 5.4% despite three Wall Street firms cutting price targets, with JP Morgan maintaining a Neutral rating. Investors appear to have factored in the downward revisions or see potential upside from the new targets.

AlphaStreet

2026-03-13

Chemours faces class action in Netherlands over PFAS emissions

2026-04-01

Chemours Director Awarded 1,305 Deferred Stock Units as Equity Compensation

2026-04-04

Chemours upsizes and prices $700 million senior notes offering

2026-04-08

Chemours Co stock hits 52-week high at $22.56

2026-04-11

Chemours Co Files 10-K, 10-Q, and 8-K Reports